TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10628631

Group type: EXPERIMENTAL
Intervention: Intravenous ranitidine
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Nasogastric sucralfate
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Maximum serum creatinine
Number of subjects: 1077
Study: 8529985

Group type: EXPERIMENTAL
Intervention: DMSO gel 25%
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo gel base
Number of subjects: 112
Study: 2036999

Group type: EXPERIMENTAL
Intervention: salm-calcitonin
Number of subjects: 0
Study: 7020816

Group type: EXPERIMENTAL
Intervention: Clomipramine (in doses recommended for use in general practice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychotherapeutic help (usual range)
Number of subjects: 0
Study: 30686575

Group type: EXPERIMENTAL
Intervention: Two-step suture technique
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 240
Study: 29179137

Group type: EXPERIMENTAL
Intervention: Group Metacognitive Therapy (MCT) for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mindfulness Based Stress Reduction (MBSR) for 8 weeks
Number of subjects: 40
Study: 26899859

Group type: EXPERIMENTAL
Intervention: Talon cusps observed in patients
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Type I talon cusp
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Type II talon cusp
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Type III talon cusp
Number of subjects: 4116
Study: 24717149

Group type: EXPERIMENTAL
Intervention: 635 nm per 6 mW laser-emitting toothbrush
Number of subjects: 96

Group type: COMPARATOR
Intervention: 635 nm per 12.9 μW light-emitting diode (LED) toothbrush
Number of subjects: 96
Study: 22305012

Group type: EXPERIMENTAL
Intervention: Protocol A (525 mgI/kg)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Protocol B (630 mgI/kg)
Number of subjects: 128
Study: 20852182

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) for 3-15 days (T1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Parenteral nutrition (PN) scheduled (T0)
Number of subjects: 46
Study: 17413908

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15632336

Group type: EXPERIMENTAL
Intervention: Pharmacy access to EC
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: Advance provision of 3 packs of levonorgestrel EC
Number of subjects: 2117

Group type: COMPARATOR
Intervention: Control group (clinic access)
Number of subjects: 2117
Study: 12384802

Group type: EXPERIMENTAL
Intervention: Vitamin E greater than 13 mg/day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vitamin C greater than 100 mg/day
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Beta-carotene, vitamin C, vitamin E, and folic acid intake
Number of subjects: 99
Study: 9771181

Group type: EXPERIMENTAL
Intervention: Propofol (up to 2.5 mg.kg‐1)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Etomidate (0.3 mg.kg‐1)
Number of subjects: 71
Study: 7800967

Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2894165

Group type: EXPERIMENTAL
Intervention: Rilmenidine
Number of subjects: 333

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 333
Study: 30352568

Group type: EXPERIMENTAL
Intervention: Supervised group training
Number of subjects: 200

Group type: COMPARATOR
Intervention: Home-based training supported by smartphones, health coaches, and Fitbit technology
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cost information
Number of subjects: 200
Study: 26936608

Group type: COMPARATOR
Intervention: Capped chemotherapy in obese patients
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Uncapped chemotherapy in obese patients
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Uncapped chemotherapy in overweight or normal bodyweight patients
Number of subjects: 325
Study: 24010867

Group type: EXPERIMENTAL
Intervention: Corrective Babbling therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Immediate treatment (IT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Delayed treatment (DT)
Number of subjects: 13
Study: 22549573

Group type: EXPERIMENTAL
Intervention: Provision of a diary to family members of patients in intensive care
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (family members who did not receive a diary)
Number of subjects: 36
Study: 19957195

Group type: EXPERIMENTAL
Intervention: PPI and rebamipide therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: PPI alone
Number of subjects: 62
Study: 18689564

Group type: EXPERIMENTAL
Intervention: Olive oil (25 mL/day)
Number of subjects: 200
Study: 15912074

Group type: EXPERIMENTAL
Intervention: Furosemide infusion
Number of subjects: 30
Study: 15355136

Group type: EXPERIMENTAL
Intervention: Critical features predicted by prior knowledge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incongruent features predicted using knowledge from other domains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contradictory features violating prior knowledge
Number of subjects: 0
Study: 10653329

Group type: EXPERIMENTAL
Intervention: LC-PUFA enriched formula
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 37

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 37
Study: 9294270

Group type: EXPERIMENTAL
Intervention: CO2 group (insufflation)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Air group (abdominal wall-lifting)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17
Study: 8279245

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol/nitrous oxide anaesthesia
Number of subjects: 60
Study: 3490396

Group type: EXPERIMENTAL
Intervention: Gunsight (GU)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Imagined gunsight (IGU)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mental arithmetic (MA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Visual tracking (VT)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Gunsight (GU) for vestibular patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Imagined gunsight (IGU) for vestibular patients
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Visual tracking (VT) for vestibular patients
Number of subjects: 13
Study: 2484393

Group type: EXPERIMENTAL
Intervention: Antioxidative cocktail (300 micrograms selenium as L‐selenomethionine, 45 mg zinc, 270 mg vitamin C, 2.7 mg vitamin A, 6 mg vitamin B‐6, 465 mg vitamin E, and 250 mg gamma‐linolenic acid daily for one year)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Antioxidative cocktail
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (similar looking pills and capsules without active components)
Number of subjects: 97
Study: 29986616

Group type: EXPERIMENTAL
Intervention: Persian version of the Identification of Functional Ankle Instability (IdFAI) questionnaire
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cumberland Ankle Instability Tool (CAIT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Foot and Ankle Ability Measure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Foot and Ankle Outcome Score
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fear Avoidance Belief questionnaire
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tampa Scale of Kinesiophobia
Number of subjects: 120
Study: 28910237

Group type: EXPERIMENTAL
Intervention: Exenatide (2 mg, subcutaneous injections, once weekly)
Number of subjects: 14752

Group type: COMPARATOR
Intervention: Placebo (matching placebo, once weekly)
Number of subjects: 14752

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 14752

Group type: COMPARATOR
Intervention: Exenatide and Placebo
Number of subjects: 14752
Study: 24830782

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp. paracasei F19 (LF19)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22342470

Group type: EXPERIMENTAL
Intervention: Standardized education workshops (3 workshops lasting 1.5 hours each) plus usual thermal therapy for 3 weeks
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual thermal therapy and non‐standardized verbal information
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Standardized education workshops
Number of subjects: 360
Study: 21749263

Group type: EXPERIMENTAL
Intervention: Infrared-LED illumination during treadmill training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (treadmill training only)
Number of subjects: 20
Study: 19167522

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 16723323

Group type: EXPERIMENTAL
Intervention: Emergency Department assessment of neuropsychological and balance deficits and pain severity in concussed individuals
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Emergency Department assessment of concussed individuals
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Neurocognitive impairment, pain, and balance deficits
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (minor orthopedic injuries and ED visitors)
Number of subjects: 29
Study: 15112270

Group type: EXPERIMENTAL
Intervention: EBV CTL infusion (5.0 x 10(6) EBV CTL/kg per dose, 3 infusions)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fludarabine (30 mg/m(2) per day for 3 days) followed by a single CTL infusion (1.5 x 10(7) EBV CTL/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fludarabine (30 mg/m(2) per day for 3 days)
Number of subjects: 6
Study: 11330994

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 6473

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 6473

Group type: EXPERIMENTAL
Intervention: Grade 7 adolescents
Number of subjects: 6473

Group type: EXPERIMENTAL
Intervention: Urban and rural adolescents
Number of subjects: 6473
Study: 9293727

Group type: EXPERIMENTAL
Intervention: Aggressive strategy for early recognition and intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional therapy and pharmacologic advances
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer interventional measures
Number of subjects: 0
Study: 7967426

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Existing BMT protocols (Belgian, American, British)
Number of subjects: 250
Study: 3665325

Group type: EXPERIMENTAL
Intervention: Theostat 300® with fasting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theostat 300® with low-fat breakfast (10 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theostat 300® with high-fat breakfast (60 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (fasting)
Number of subjects: 12
Study: 30015793

Group type: EXPERIMENTAL
Intervention: Triple-NRTI regimen (abacavir/zidovudine/lamivudine)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Dual-NRTI + PI regimen (lopinavir/ritonavir/zidovudine/lamivudine)
Number of subjects: 197
Study: 28297590

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention for older persons with schizophrenia (June 2008 to May 2014)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Diffusion tensor imaging and genetics study of psychosis across the life span (February 2007 to December 2013)
Number of subjects: 171
Study: 26281825

Group type: EXPERIMENTAL
Intervention: Radiation therapy for painful bone metastases
Number of subjects: 956
Study: 23006823

Group type: EXPERIMENTAL
Intervention: 0.4% Stannous fluoride (SnF(2))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.15% Titanium tetrafluoride (TiF(4))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.2% Sodium fluoride (NaF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no fluoride treatment)
Number of subjects: 16
Study: 21419321

Group type: EXPERIMENTAL
Intervention: 200 μg of selenium as glycinate for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 18207120

Group type: EXPERIMENTAL
Intervention: Peripheral retinal laser ablation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Untreated avascular retina
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: All 10 eyes
Number of subjects: 5
Study: 16372389

Group type: EXPERIMENTAL
Intervention: van Elteren test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 14668778

Group type: EXPERIMENTAL
Intervention: Resting perfusion defects (PDs)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Stress-induced perfusion defects (PDs)
Number of subjects: 139
Study: 10620203

Group type: EXPERIMENTAL
Intervention: CsA + BO
Number of subjects: 0

Group type: COMPARATOR
Intervention: CsA + placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose of BO
Number of subjects: 0
Study: 8644056

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8300

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8300
Study: 1906718

Group type: EXPERIMENTAL
Intervention: Glass ionomer liner and posterior composite resin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glass ionomer silver cermet placed in the proximal box to the contact area and the remainder restored with posterior composite resin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glass ionomer silver cermet only
Number of subjects: 30

Group type: COMPARATOR
Intervention: All techniques (1, 2, and 3)
Number of subjects: 30
Study: 6336863

Group type: EXPERIMENTAL
Intervention: Metronidazole (oral or intravenous)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole administered 1 hour before and at 8 and 16 hours after the operation
Number of subjects: 181

Group type: COMPARATOR
Intervention: Erythromycin and neomycin as preoperative bowel preparations
Number of subjects: 181
Study: 31778194

Group type: EXPERIMENTAL
Intervention: Hyperimmune anti-influenza plasma treatment in the FluPlasma trial
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Self-administered live-attenuated influenza vaccine in the SNIF trial
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: InFLUenza Patient-Reported Outcome (FLU-PRO) survey
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Three types of licensed vaccines in the PAIVED study
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Flu Breath Test (FBT) study
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Study to Address Threats of ARI in Congregate Military Populations (ATARI)
Number of subjects: 2000
Study: 29614719

Group type: EXPERIMENTAL
Intervention: Melon concentrate application and/or supplementation
Number of subjects: 0
Study: 27165651

Group type: EXPERIMENTAL
Intervention: School-based violence prevention programme involving teacher training in classroom behaviour management and strategies to promote children's social-emotional competence, delivered through five full-day workshops, monthly in-class coaching over 2 school terms, and weekly text messages.
Number of subjects: 912
Study: 24465407

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) patients with MS
Number of subjects: 66

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 66
Study: 22317852

Group type: EXPERIMENTAL
Intervention: Low dose prednisone (1 mg × kg × day for 4 weeks, then reduced to 5mg every 2 weeks up to 10mg) combined with cyclophosphamide (monthly for 6 months, then twice-monthly for 6 months)
Number of subjects: 23

Group type: COMPARATOR
Intervention: High dose prednisone (10mg daily) combined with cyclophosphamide (ev)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (low dose and high dose)
Number of subjects: 23
Study: 20196964

Group type: EXPERIMENTAL
Intervention: 6.6 g PUFA/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.0 g PUFA/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control oil (olive oil)
Number of subjects: 60
Study: 19000316

Group type: EXPERIMENTAL
Intervention: Routine computerized HRQoL measurement
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Physicians' access to computerized HRQoL information
Number of subjects: 587
Study: 16032936

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg/dose salbutamol (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of lower‐dose salbutamol (0.10 mg/kg/dose) and ipratropium bromide (5 mcg/kg/dose) (group 2)
Number of subjects: 20
Study: 12014521

Group type: EXPERIMENTAL
Intervention: Supervised training for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unsupervised training for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise training (both supervised and unsupervised)
Number of subjects: 24
Study: 11072387

Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes after nicotine deprivation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tobacco deprivation
Number of subjects: 20
Study: 8653220

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-modified Dermatophagoides pteronyssinus extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmodified Dermatophagoides pteronyssinus extract
Number of subjects: 0
Study: 2219608

Group type: EXPERIMENTAL
Intervention: Allopurinol alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Allopurinol and thiazide
Number of subjects: 87
Study: 69596

Group type: EXPERIMENTAL
Intervention: organo-heparinoid ointment (Hirudoid 40,000)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo ointment
Number of subjects: 40
Study: 31519795

Group type: COMPARATOR
Intervention: Pre-TPD compliance
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Post-TPD compliance
Number of subjects: 107

Group type: COMPARATOR
Intervention: Overall compliance pre-TPD
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Overall compliance post-TPD
Number of subjects: 107
Study: 31099214

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with cinesiotherapy cupping
Number of subjects: 78

Group type: COMPARATOR
Intervention: Acupuncture combined with conventional cupping
Number of subjects: 78
Study: 28258819

Group type: EXPERIMENTAL
Intervention: Parent health report intervention
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study: 23647357

Group type: EXPERIMENTAL
Intervention: High-leucine whey protein hydrolysate + carbohydrate (WHD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Carbohydrate (PLA)
Number of subjects: 22
Study: 23838148

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of astragalosides injection (AI) at 200 ml
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of astragalosides injection (AI) at 300 ml
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of astragalosides injection (AI) at 400 ml
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of astragalosides injection (AI) at 500 ml
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Repeated intravenous infusion of astragalosides injection (AI)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Adverse events after administration of AI
Number of subjects: 4
Study: 20415992

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 13

Group type: COMPARATOR
Intervention: Benzathine penicillin
Number of subjects: 13
Study: 18715274

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg dose of alcohol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 13
Study: 16544086

Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES) applied to the submental muscles for ten 1‐h treatments over two weeks.
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (A condition) during the control phase.
Number of subjects: 10
Study: 12627929

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Docetaxel plus thalidomide
Number of subjects: 70
Study: 11938810

Group type: EXPERIMENTAL
Intervention: 120 mg of ligustrazine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 240 mg of ligustrazine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 480 mg of ligustrazine
Number of subjects: 69
Study: 1514168

Group type: EXPERIMENTAL
Intervention: GR32191 (40 mg) + heparin (5,000 IU bolus + 1,000 IU/h for 3 h)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GR32191 (80 mg) + heparin (5,000 IU bolus + 1,000 IU/h for 3 h)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GR32191 (40 mg) + placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GR32191 (80 mg) + placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: heparin + placebo
Number of subjects: 18
Study: 6098035

Group type: EXPERIMENTAL
Intervention: Penicillin-sulbactam regimen (aqueous procaine penicillin G, sulbactam, and probenecid)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Spectinomycin
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Penicillin-sulbactam regimen
Number of subjects: 193
Study: 31539833

Group type: EXPERIMENTAL
Intervention: Dampening instructions
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Amplifying instructions
Number of subjects: 89

Group type: COMPARATOR
Intervention: No instruction control
Number of subjects: 89
Study: 29800212

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 848

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 848
Study: 26130292

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day for 6 weeks, then 10 mg/day for 18 weeks (total 24 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 24471662

Group type: EXPERIMENTAL
Intervention: End-hole catheter
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Triple-hole catheter
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Six-hole catheter
Number of subjects: 156
Study: 22362830

Group type: EXPERIMENTAL
Intervention: Brief Mobile Treatment (BMT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 68